McGill, iSAEC Partner on TB Drug Reactions | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Montreal's McGill University will partner with the International Serious Adverse Events Consortium (iSAEC) to enable studies of the genetic basis of adverse reactions to Tuberculosis treatment.

The iSAEC's International Drug Induced Liver Injury Consortium (IDILIC) currently is recruiting patients with serious liver injuries from drugs and McGill is serving as the coordinating center for an international randomized trial for the treatment of latent TB.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.